Docusign Inc vs Erasca Inc. Common Stock — how do they compare? Docusign Inc trades at $70.88 (market cap $13.35B), while Erasca Inc. Common Stock trades at $15.97 (market cap $5.40B). The key difference: Docusign Inc is far larger — about 2.5× Erasca Inc. Common Stock's market cap, and Docusign Inc is trading nearer its 52-week high, Erasca Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Erasca Inc. Common Stock for 0 Days on average.
| DOCU | ERAS | |
|---|---|---|
Market Cap | $13.35B | $5.40B |
Volume | 3,158,858 | 9,533,185 |
Sector | Technology | Health |
52-Week High | $73.14 | $22.47 |
52-Week Low | $41.75 | $2.20 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $12.76B | $5.18B |
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.08, up 3.16% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is solid, and profitability metrics like net income margin and ROE show significant improvement. Recent news highlights AI integration in contract processing and leadership in workflow software, though insider selling has been noted.
The outlook for DOCU is positive, driven by earnings beats and AI adoption, but risks include valuation concerns with a P/E of 43.55 and insider selling. The consensus price target of $68.75 suggests limited upside from current levels, indicating a cautious stance from analysts despite bullish technical signals.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →